France imposes millionaire fine on pharmaceutical companies for anti-obesity advertising

France has taken a firm stance against pharmaceutical advertising practices related to obesity treatments, imposing significant fines on major companies like Novo Nordisk and Eli Lilly. The National Agency for the Safety of Medicines (ANSM) cited concerns that public advertising for prescription drugs, particularly GLP-1 analogs such as Saxenda, Wegovy, and Mounjaro, could mislead the public. This action underscores France's commitment to regulating its healthcare market and protecting citizens from potentially harmful or misleading health information, especially in a climate where these drugs are increasingly sought for cosmetic weight loss.

“

susceptibles d'induire le public en erreur dans un contexte marqué par une forte médiatisation et un usage détourné croissant des analogues du GLP-1 (aGLP-1), notamment à des fins d’amincissement à visée esthétique

The ANSM's decision highlights the specific risks associated with promoting powerful medications to a broad audience through social media, posters, and print. The agency emphasized that such campaigns are "susceptible of misleading the public in a context marked by strong mediatization and a growing misuse of GLP-1 analogs, especially for weight loss for aesthetic reasons." This reflects a broader European concern about the ethical implications of marketing drugs that have significant physiological effects, particularly when their use might extend beyond medically indicated purposes.

“

rejette fermement la décision de l'organisme et qu'elle étudie la possibilité de faire appel

Novo Nordisk France has strongly contested the ANSM's ruling, indicating its intention to appeal. The company argues that its advertising was appropriate and that it rejects the agency's decision. Eli Lilly France, while acknowledging the fine, maintained that its awareness campaign adhered to the applicable framework for human health communications. These differing perspectives reveal the tension between regulatory oversight aimed at public health and the commercial interests of pharmaceutical companies, a dynamic that plays out globally but is particularly scrutinized in markets like France with robust consumer protection laws.

“

prenait acte de la décision et estimait que sa campagne de sensibilisation diffusée en avril 2025 était « conforme au cadre applicable aux communications relatives à la santé humaine »